Literature DB >> 22795689

Case-control association analysis of polymorphisms in the δ-opioid receptor, OPRD1, with cocaine and opioid addicted populations.

R C Crist1, L M Ambrose-Lanci, M Vaswani, T K Clarke, A Zeng, C Yuan, T N Ferraro, H Hakonarson, K M Kampman, C A Dackis, H M Pettinati, C P O'Brien, D W Oslin, G A Doyle, F W Lohoff, W H Berrettini.   

Abstract

BACKGROUND: Addiction susceptibility and treatment responsiveness are greatly influenced by genetic factors. Sequence variation in genes involved in the mechanisms of drug action have the potential to influence addiction risk and treatment outcome. The opioid receptor system is involved in mediating the rewarding effects of cocaine and opioids. The μ-opioid receptor (MOR) has traditionally been considered the primary target for opioid addiction. The MOR, however, interacts with and is regulated by many known MOR interacting proteins (MORIPs), including the δ-opioid receptor (DOR).
METHODS: The present study evaluated the contribution of OPRD1, the gene encoding the DOR, to the risk of addiction to opioids and cocaine. The association of OPRD1 polymorphisms with both opioid addiction (OA) and cocaine addiction (CA) was analyzed in African American (OA n=336, CA n=503) and European American (OA n=1007, CA n=336) populations.
RESULTS: The primary finding of this study is an association of rs678849 with cocaine addiction in African Americans (allelic p=0.0086). For replication purposes, this SNP was analyzed in a larger independent population of cocaine addicted African Americans and controls and the association was confirmed (allelic p=4.53 × 10(-5); n=993). By performing a meta-analysis on the expanded populations, the statistical evidence for an association was substantially increased (allelic p=8.5 × 10(-7)) (p-values non-FDR corrected).
CONCLUSION: The present study suggests that polymorphisms in OPRD1 are relevant for cocaine addiction in the African American population and provides additional support for a broad role for OPRD1 variants in drug dependence.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22795689      PMCID: PMC3509227          DOI: 10.1016/j.drugalcdep.2012.06.023

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  52 in total

1.  Controlling the false discovery rate in behavior genetics research.

Authors:  Y Benjamini; D Drai; G Elmer; N Kafkafi; I Golani
Journal:  Behav Brain Res       Date:  2001-11-01       Impact factor: 3.332

2.  Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins.

Authors:  Kenneth S Kendler; Kristen C Jacobson; Carol A Prescott; Michael C Neale
Journal:  Am J Psychiatry       Date:  2003-04       Impact factor: 18.112

3.  Mu opioid receptor gene polymorphisms and heroin dependence in Asian populations.

Authors:  Ene-Choo Tan; Chay-Hoon Tan; Umavathy Karupathivan; Eric P H Yap
Journal:  Neuroreport       Date:  2003-03-24       Impact factor: 1.837

4.  A genetic association study of the mu opioid receptor and severe opioid dependence.

Authors:  James J Crowley; David W Oslin; Ashwin A Patkar; Edward Gottheil; Peter A DeMaria; Charles P O'Brien; Wade H Berrettini; Dorothy E Grice
Journal:  Psychiatr Genet       Date:  2003-09       Impact factor: 2.458

Review 5.  Opioid receptor types and subtypes: the delta receptor as a model.

Authors:  P A Zaki; E J Bilsky; T W Vanderah; J Lai; C J Evans; F Porreca
Journal:  Annu Rev Pharmacol Toxicol       Date:  1996       Impact factor: 13.820

6.  Rewarding effects of ethanol and cocaine in mu opioid receptor-deficient mice.

Authors:  Axel Becker; Gisela Grecksch; Jürgen Kraus; Horace H Loh; Helmut Schroeder; Volker Höllt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2002-02-21       Impact factor: 3.000

7.  Association between mu opioid receptor gene polymorphisms and Chinese heroin addicts.

Authors:  C Y Szeto; N L Tang; D T Lee; A Stadlin
Journal:  Neuroreport       Date:  2001-05-08       Impact factor: 1.837

8.  Involvement of the kappa-opioid receptor in the anxiogenic-like effect of CP 55,940 in male rats.

Authors:  S Marín; E Marco; M Biscaia; B Fernández; M Rubio; C Guaza; H Schmidhammer; M P Viveros
Journal:  Pharmacol Biochem Behav       Date:  2003-02       Impact factor: 3.533

9.  Relationship of the delta-opioid receptor gene to heroin abuse in a large Chinese case/control sample.

Authors:  Ke Xu; Xie-he Liu; Saumya Nagarajan; Xiao-Yong Gu; David Goldman
Journal:  Am J Med Genet       Date:  2002-06-01

10.  Endogenous opioid receptor genes and alcohol dependence among Taiwanese Han.

Authors:  El Wui Loh; Cathy S J Fann; Yuh Terng Chang; Ching Jui Chang; Andrew T A Cheng
Journal:  Alcohol Clin Exp Res       Date:  2004-01       Impact factor: 3.455

View more
  23 in total

Review 1.  Pharmacogenetics of alcohol use disorder treatments: an update.

Authors:  Emily E Hartwell; Henry R Kranzler
Journal:  Expert Opin Drug Metab Toxicol       Date:  2019-06-11       Impact factor: 4.481

Review 2.  A review of pharmacogenetic studies of substance-related disorders.

Authors:  Jermaine D Jones; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2015-03-18       Impact factor: 4.492

Review 3.  Recent advances on the δ opioid receptor: from trafficking to function.

Authors:  Louis Gendron; Nitish Mittal; Hélène Beaudry; Wendy Walwyn
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

Review 4.  Environmental, genetic and epigenetic contributions to cocaine addiction.

Authors:  R Christopher Pierce; Bruno Fant; Sarah E Swinford-Jackson; Elizabeth A Heller; Wade H Berrettini; Mathieu E Wimmer
Journal:  Neuropsychopharmacology       Date:  2018-02-05       Impact factor: 7.853

Review 5.  Pharmacogenomics of Pain Management: The Impact of Specific Biological Polymorphisms on Drugs and Metabolism.

Authors:  Elyse M Cornett; Michelle A Carroll Turpin; Allison Pinner; Pankaj Thakur; Tamizh Selvan Gnana Sekaran; Harish Siddaiah; Jasmine Rivas; Anna Yates; G Jason Huang; Anitha Senthil; Narjeet Khurmi; Jenna L Miller; Cain W Stark; Richard D Urman; Alan David Kaye
Journal:  Curr Oncol Rep       Date:  2020-02-06       Impact factor: 5.075

6.  A commonly carried genetic variant in the delta opioid receptor gene, OPRD1, is associated with smaller regional brain volumes: replication in elderly and young populations.

Authors:  Florence F Roussotte; Neda Jahanshad; Derrek P Hibar; Elizabeth R Sowell; Omid Kohannim; Marina Barysheva; Narelle K Hansell; Katie L McMahon; Greig I de Zubicaray; Grant W Montgomery; Nicholas G Martin; Margaret J Wright; Arthur W Toga; Clifford R Jack; Michael W Weiner; Paul M Thompson
Journal:  Hum Brain Mapp       Date:  2013-02-21       Impact factor: 5.038

7.  An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans.

Authors:  Richard C Crist; Toni-Kim Clarke; Alfonso Ang; Lisa M Ambrose-Lanci; Falk W Lohoff; Andrew J Saxon; Walter Ling; Maureen P Hillhouse; R Douglas Bruce; George Woody; Wade H Berrettini
Journal:  Neuropsychopharmacology       Date:  2013-04-23       Impact factor: 7.853

8.  A delta-opioid receptor genetic variant is associated with abstinence prior to and during cocaine dependence treatment.

Authors:  R C Crist; G A Doyle; K M Kampman; W H Berrettini
Journal:  Drug Alcohol Depend       Date:  2016-07-14       Impact factor: 4.492

Review 9.  Delta opioid receptors in brain function and diseases.

Authors:  Paul Chu Sin Chung; Brigitte L Kieffer
Journal:  Pharmacol Ther       Date:  2013-06-10       Impact factor: 12.310

10.  Case-control association study of WLS variants in opioid and cocaine addicted populations.

Authors:  Richard C Crist; Lisa M Ambrose-Lanci; Angela Zeng; Cindy Yuan; Kyle M Kampman; Helen M Pettinati; David W Oslin; Charles P O'Brien; Thomas N Ferraro; Glenn A Doyle; Falk W Lohoff; Wade H Berrettini
Journal:  Psychiatry Res       Date:  2013-04-05       Impact factor: 3.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.